DrugPatentWatch Database Preview
EISAI INC Company Profile
» See Plans and Pricing
What is the competitive landscape for EISAI INC, and what generic alternatives to EISAI INC drugs are available?
EISAI INC has sixteen approved drugs.
There are thirty-two US patents protecting EISAI INC drugs.
There are six hundred and ninety-one patent family members on EISAI INC drugs in fifty-five countries and sixty supplementary protection certificates in seventeen countries.
Summary for EISAI INC
| International Patents: | 691 |
| US Patents: | 32 |
| Tradenames: | 12 |
| Ingredients: | 10 |
| NDAs: | 16 |
| Drug Master File Entries: | 1 |
Drugs and US Patents for EISAI INC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eisai Inc | BANZEL | rufinamide | TABLET;ORAL | 021911-002 | Nov 14, 2008 | AB | RX | Yes | No | 6,740,669*PED | Start Trial | Y | Start Trial | ||
| Eisai Inc | ARICEPT ODT | donepezil hydrochloride | TABLET, ORALLY DISINTEGRATING;ORAL | 021720-002 | Oct 18, 2004 | DISCN | Yes | No | Start Trial | Start Trial | |||||
| Eisai Inc | DAYVIGO | lemborexant | TABLET;ORAL | 212028-002 | Apr 7, 2020 | RX | Yes | Yes | 8,268,848 | Start Trial | Y | Y | Start Trial | ||
| Eisai Inc | FYCOMPA | perampanel | TABLET;ORAL | 202834-002 | Oct 22, 2012 | RX | Yes | No | 6,949,571 | Start Trial | Y | Y | Start Trial | ||
| Eisai Inc | BELVIQ | lorcaserin hydrochloride | TABLET;ORAL | 022529-001 | Jun 27, 2012 | DISCN | Yes | No | 9,169,213 | Start Trial | Start Trial | ||||
| Eisai Inc | LENVIMA | lenvatinib mesylate | CAPSULE;ORAL | 206947-002 | Feb 13, 2015 | RX | Yes | Yes | Start Trial | Start Trial | |||||
| Eisai Inc | BELVIQ | lorcaserin hydrochloride | TABLET;ORAL | 022529-001 | Jun 27, 2012 | DISCN | Yes | No | 8,946,207 | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for EISAI INC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Eisai Inc | ARICEPT | donepezil hydrochloride | TABLET;ORAL | 020690-002 | Nov 25, 1996 | 6,372,760 | Start Trial |
| Eisai Inc | BANZEL | rufinamide | SUSPENSION;ORAL | 201367-001 | Mar 3, 2011 | 7,750,028*PED | Start Trial |
| Eisai Inc | ARICEPT | donepezil hydrochloride | TABLET;ORAL | 020690-002 | Nov 25, 1996 | 4,895,841 | Start Trial |
| Eisai Inc | HALAVEN | eribulin mesylate | SOLUTION;INTRAVENOUS | 201532-001 | Nov 15, 2010 | 6,469,182 | Start Trial |
| Eisai Inc | BANZEL | rufinamide | TABLET;ORAL | 021911-003 | Nov 14, 2008 | 7,750,028*PED | Start Trial |
| Eisai Inc | LUSEDRA | fospropofol disodium | SOLUTION;INTRAVENOUS | 022244-001 | Dec 12, 2008 | 6,872,838 | Start Trial |
| Eisai Inc | ACIPHEX | rabeprazole sodium | TABLET, DELAYED RELEASE;ORAL | 020973-002 | Aug 19, 1999 | 5,045,552*PED | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for EISAI INC drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 23 mg | ➤ Subscribe | 2013-07-09 |
| ➤ Subscribe | Oral Suspension | 40 mg/mL | ➤ Subscribe | 2014-06-16 |
| ➤ Subscribe | Extended-release Tablets | 20 mg | ➤ Subscribe | 2016-12-13 |
| ➤ Subscribe | Tablets | 10 mg | ➤ Subscribe | 2016-06-27 |
| ➤ Subscribe | Capsules | 4 mg and 10 mg | ➤ Subscribe | 2019-02-13 |
| ➤ Subscribe | Tablets | 100 mg, 200 mg and 400 mg | ➤ Subscribe | 2012-11-14 |
| ➤ Subscribe | Tablets | 2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg | ➤ Subscribe | 2016-10-24 |
| ➤ Subscribe | Orally Disintegrating Tablets | 5 mg and 10 mg | ➤ Subscribe | 2010-06-30 |
International Patents for EISAI INC Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 2332920 | Start Trial |
| Hungary | E028976 | Start Trial |
| Australia | 725528 | Start Trial |
| Australia | 2005320547 | Start Trial |
| Denmark | 1838677 | Start Trial |
| World Intellectual Property Organization (WIPO) | 03086306 | Start Trial |
| Spain | 2197485 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for EISAI INC Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1415987 | 553 | Finland | Start Trial | |
| 1300396 | 420 | Finland | Start Trial | |
| 1087960 | SPC/GB11/039 | United Kingdom | Start Trial | PRODUCT NAME: ERIBULIN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT.; REGISTERED: UK EU/1/11/678/001 20110317; UK EU/1/11/678/002 20110317 |
| 0994863 | SPC026/2007 | Ireland | Start Trial | SPC026/2007: 20071026, EXPIRES: 20220115 |
| 0994863 | CA 2007 00037 | Denmark | Start Trial | PRODUCT NAME: RUFINAMID, KRYSTALMODIFIKATION A |
| 1300396 | 12C0074 | France | Start Trial | PRODUCT NAME: PERAMPANEL, SEL DE CELUI-CI OU HYDRATE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/12/776/001 20120723 |
| 1415987 | 122015000083 | Germany | Start Trial | PRODUCT NAME: LENVATINIB ODER EINES SEINER PHARMAZEUTISCH AKZEPTABLEN SALZE ODER EINES SEINER HYDRATE; REGISTRATION NO/DATE: EU/1/15/1002/001-002 20150528 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
